419 related articles for article (PubMed ID: 10741298)
1. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
2. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
[TBL] [Abstract][Full Text] [Related]
3. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
Sengeløv L; Kamby C; Lund B; Engelholm SA
J Clin Oncol; 1998 Oct; 16(10):3392-7. PubMed ID: 9779718
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
Uhm JE; Lim HY; Kim WS; Choi HY; Lee HM; Park BB; Park K; Kang WK
Neoplasia; 2007 Jan; 9(1):18-22. PubMed ID: 17325740
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 May; 15(5):1853-7. PubMed ID: 9164195
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
Redman BG; Smith DC; Flaherty L; Du W; Hussain M
J Clin Oncol; 1998 May; 16(5):1844-8. PubMed ID: 9586899
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
16. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
Igawa M; Kadena H; Ueda M; Usui T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
Garcia del Muro X; Marcuello E; Gumá J; Paz-Ares L; Climent MA; Carles J; Parra MS; Tisaire JL; Maroto P; Germá JR
Br J Cancer; 2002 Feb; 86(3):326-30. PubMed ID: 11875692
[TBL] [Abstract][Full Text] [Related]
18. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
Mulatero C; McClaren BR; Mason M; Oliver RT; Gallagher CJ
Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
